CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dimension Therapeutics, Inc. (“Dimension” or the “Company”) a gene therapy company advancing novel treatments for hemophilia and rare diseases, today announced that Eric Crombez, M.D., former senior medical director, Global Clinical Development, at Shire plc, has been appointed to the newly created position of Chief Medical Officer. Dr. Crombez will lead Dimension’s team advancing the company’s development pipeline of novel gene therapy candidates into clinical testing. Dimension’s lead, wholly owned program in hemophilia B is anticipated to enter clinical testing in 2015. Dr. Crombez will report directly to Dimension’s CEO Annalisa Jenkins, MBBS, MRCP. In addition, Dimension today announced the appointment of Stephanie Haller, Shire’s former director, Clinical Programs, Early Phase Development, to the newly created position of Vice President of Clinical Operations. The appointments of Dr. Crombez and Ms. Haller are effective immediately.
Help employers find you! Check out all the jobs and post your resume.
